Beyond market trends, investors looking for superior returns explore the world of stock picking. The right selections can be a powerful driver for wealth accumulation.
Ultragenyx Pharmaceutical Inc (NASDAQ: RARE) closed the day trading at $33.21 down -3.29% from the previous closing price of $34.34. In other words, the price has decreased by -$3.29 from its previous closing price. On the day, 1.78 million shares were traded. RARE stock price reached its highest trading level at $34.64 during the session, while it also had its lowest trading level at $32.845.
Ratios:
For a better understanding of RARE, let’s look at its different ratios. For the most recent quarter (mrq), Quick Ratio is recorded 1.74 and its Current Ratio is at 1.89. In the meantime, Its Debt-to-Equity ratio is 94.23 whereas as Long-Term Debt/Eq ratio is at 85.75.
Upgrades & Downgrades
In the most recent recommendation for this company, Wells Fargo on October 20, 2025, initiated with a Overweight rating and assigned the stock a target price of $65.
Insider Transactions:
The insider trade also gives investors a glimpse into the future direction of stock prices, which can be beneficial to investors. A recent insider transaction in this stock occurred on Dec 10 ’25 when Horn Howard sold 3,081 shares for $36.38 per share. The transaction valued at 112,087 led to the insider holds 95,146 shares of the business.
HOWARD HORN bought 3,081 shares of RARE for $112,087 on Dec 10 ’25. On Oct 13 ’25, another insider, Horn Howard, who serves as the Chief Financial Officer of the company, sold 7,942 shares for $31.51 each. As a result, the insider received 250,252 and left with 98,227 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, RARE now has a Market Capitalization of 3204019968 and an Enterprise Value of 3643138560. For the stock, the TTM Price-to-Sale (P/S) ratio is 5.08 while its Price-to-Book (P/B) ratio in mrq is 349.06. Its current Enterprise Value per Revenue stands at 5.777 whereas that against EBITDA is -7.162.
Stock Price History:
The Beta on a monthly basis for RARE is 0.12, which has changed by -0.2100299 over the last 52 weeks, in comparison to a change of 0.15905356 over the same period for the S&P500. Over the past 52 weeks, RARE has reached a high of $46.50, while it has fallen to a 52-week low of $25.81. The 50-Day Moving Average of the stock is -1.34%, while the 200-Day Moving Average is calculated to be -1.29%.
Shares Statistics:
Over the past 3-months, RARE traded about 1.49M shares per day on average, while over the past 10 days, RARE traded about 1641410 shares per day. A total of 96.27M shares are outstanding, with a floating share count of 89.77M. Insiders hold about 6.95% of the company’s shares, while institutions hold 99.09% stake in the company. Shares short for RARE as of 1764288000 were 8871538 with a Short Ratio of 5.96, compared to 1761868800 on 7144800. Therefore, it implies a Short% of Shares Outstanding of 8871538 and a Short% of Float of 9.520000000000001.
Earnings Estimates
Ultragenyx Pharmaceutical Inc (RARE) is presently subject to a detailed evaluation by 12.0 analysts, each offering their unique perspectives on its market standing.The consensus estimate for the next quarter is -$1.47, with high estimates of -$0.91 and low estimates of -$1.77.
Analysts are recommending an EPS of between -$5.33 and -$6.41 for the fiscal current year, implying an average EPS of -$5.77. EPS for the following year is -$4.47, with 12.0 analysts recommending between -$2.68 and -$6.41.
Revenue Estimates
16 analysts predict $188.05M in revenue for. The current quarter. It ranges from a high estimate of $197M to a low estimate of $175.1M. As of. The current estimate, Ultragenyx Pharmaceutical Inc’s year-ago sales were $164.88MFor the next quarter, 16 analysts are estimating revenue of $172.08M. There is a high estimate of $197.47M for the next quarter, whereas the lowest estimate is $145M.
A total of 19 analysts have provided revenue estimates for RARE’s current fiscal year. The highest revenue estimate was $667.91M, while the lowest revenue estimate was $641.7M, resulting in an average revenue estimate of $655.17M. In the same quarter a year ago, actual revenue was $560.23MBased on 19 analysts’ estimates, the company’s revenue will be $795.59M in the next fiscal year. The high estimate is $886.7M and the low estimate is $675.4M.
